Bipartisan political squabbling over drug prices has already cost biotech companies $21 billion By: MarketWatch July 24, 2017 at 05:22 AM EDT Michael Brush does the math and says that could have funded the development of 15 to 20 drugs. Read More >> Related Stocks: Abbott Laboratories Amgen Bristol-Myers Squibb Eli Lilly Gilead Sciences Johnson & Johnson Merck & Co Nasdaq Biotechnology Ishares ETF Nasdaq Composite Pfizer S&P Biotech SPDR